A multicentre placebo controlled discontinuation study of methylphenidate

This study is exploring a mental health research question for people with adhd. The research team can explain what participation involves. Direct benefit is not guaranteed. The detailed objective is not always clearly listed in the public registry; the study team can confirm.

The study type is not clearly categorized in the public registry. Focus on the objective, required tasks, visits, any intervention, and eligibility criteria, then ask the study team to confirm.

This study may concern people with adhd. The criteria appear fairly broad, but you should not assume you are eligible. The study team must confirm diagnosis, age, exclusions, available locations, and next steps.

The public registry does not clearly describe all participation steps. The listed study locations suggest that at least part of participation may involve a physical site. Ask whether some steps can be done remotely.

The public registry appears to mention rules about current treatment, stability, stopping treatment, or dose changes. Do not change your treatment for a study without medical guidance. Ask the study team and your clinician what is required, what is not allowed, and how safety is monitored.

The listed study locations suggest that at least part of participation may involve a physical site. Ask which sites are open, how many visits are expected, whether any steps can be done remotely, and whether travel costs or compensation are listed.

This study is sponsored by UMCG, which appears to be unknown or unclear. If available, it can be useful to check the sponsor website, collaborators, investigator affiliation, and the official registry before deciding. HopeStage does not judge the quality of a sponsor or researcher, but helps you identify what to verify.

The recruitment status is not clearly listed. Check the official registry or contact the study team.